Loading institutional data...
Loading institutional data...
Institutional accumulation: ownership increased +0.65% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Ownership trend chart requires at least 2 quarters of data.
More quarterly data is being processed.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -121%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2021 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Top 11 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.3M 100.0% | $5.4M 100.0% | $5.3M 100.0% | $18.9M 100.0% | $7.2M 100.0% | $6.7M 100.0% | $5.2M 100.0% | $5.6M 100.0% | $5.8M 100.0% | $5.1M 100.0% |
| Cost of Revenue | $4.8M 90.6% | $4.8M 88.7% | $4.9M 91.6% | $15.9M 84.2% | $6.8M 94.9% | $5.0M 74.0% | $3.9M 75.2% | $3.8M 68.5% | $3.8M 65.1% | $3.6M 70.3% |
| Gross Profit | $498K 9.4% | $611K 11.3% | $446K 8.4% | $3.0M 15.8% | $366K 5.1% | $1.7M 26.0% | $1.3M 24.8% | $1.8M 31.5% | $2.0M 34.9% | $1.5M 29.7% |
| Research & Development | $1.0M 19.3% | $1.5M 27.5% | $1.6M 29.7% | $1.8M 9.6% | $2.2M 30.5% | $1.9M 28.9% | $1.7M 32.3% | $1.4M 25.1% | $1.1M 19.5% | $780K 15.2% |
| Selling, General & Admin | $4.6M 86.8% | $5.5M 101.3% | $6.1M 114.0% | $5.7M 30.2% | $5.7M 78.8% | $2.5M 38.1% | $2.0M 39.0% | $1.8M 33.0% | $1.8M 31.9% | $1.6M 30.6% |
| Total Operating Expenses | $5.6M 106.1% | $7.0M 128.9% | $7.7M 143.6% | $7.5M 39.8% | $7.9M 109.3% | $4.5M 66.9% | $3.7M 71.2% | $3.2M 58.2% | $3.0M 51.4% | $2.4M 45.7% |
| Operating Income | -$5.1M -96.7% | -$6.4M -117.6% | -$7.2M -135.3% | -$4.5M -24.0% | -$7.5M -104.2% | -$2.7M -41.0% | -$2.4M -46.4% | -$1.5M -26.6% | -$955K -16.5% | -$827K -16.1% |
| Interest Expense | — | — | — | — | $367 0.0% | $9 0.0% | $47 0.0% | $37 0.0% | $282 0.0% | $167 0.0% |
| Other Income (Expense), net | $165K 3.1% | $431K 8.0% | $134K 2.5% | $27K 0.1% | $66K 0.9% | $71K 1.1% | $44K 0.8% | $48K 0.9% | $46K 0.8% | $31K 0.6% |
| Pretax Income | -$5.0M -93.6% | -$5.9M -109.6% | -$7.1M -132.8% | -$4.5M -23.9% | -$7.4M -103.3% | -$2.7M -39.9% | -$2.4M -45.5% | -$1.4M -25.8% | -$909K -15.7% | -$796K -15.5% |
| Income Tax Expense | $1K 0.0% | $42K 0.8% | $51K 1.0% | $24K 0.1% | $13K 0.2% | $7K 0.1% | $24K 0.5% | $32K 0.6% | — | $704K 13.7% |
| Net Income | -$5.0M -93.6% | -$6.0M -110.4% | -$7.1M -133.7% | -$4.5M -24.0% | -$7.4M -103.4% | -$2.7M -40.0% | -$2.4M -46.0% | -$1.5M -26.3% | -$909K -15.7% | -$1.5M -29.2% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.16 | $-2.84 | $-0.50 | $-0.36 | $-0.62 | $-0.26 | $-0.26 | $-0.17 | $-0.11 | $-0.20 |
| EPS (Diluted) | $-2.16 | $-2.84 | $-0.50 | $-0.36 | $-0.62 | $-0.26 | $-0.26 | $-0.17 | $-0.11 | $-0.20 |
| Weighted Avg Shares (Basic) | 2.3M | 2.1M | 14.2M | 12.7M | 11.9M | 10.2M | 9.2M | 8.6M | 8.3M | 7.6M |
| Weighted Avg Shares (Diluted) | 2.3M | 2.1M | 14.2M | 12.7M | 11.9M | 10.2M | 9.2M | 8.6M | 8.3M | 7.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| BMRA | $6M | — | — | 1.1× | -1.9% | 9.4% | -93.6% | -121% | -121% | — | 11 |
Peers = companies sharing BMRA's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
No standout strengths flagged.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 10.1× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 68.5 | 75.2 | 74.0 | 94.9 | 84.2 | 91.6 | 88.7 | 90.6 |
| Gross Profit | 31.5 | 24.8 | 26.0 | 5.1 | 15.8 | 8.4 | 11.3 | 9.4 |
| R&D | 25.1 | 32.3 | 28.9 | 30.5 | 9.6 | 29.7 | 27.5 | 19.3 |
| SG&A | 33.0 | 39.0 | 38.1 | 78.8 | 30.2 | 114.0 | 101.3 | 86.8 |
| Operating Income | -26.6 | -46.4 | -41.0 | -104.2 | -24.0 | -135.3 | -117.6 | -96.7 |
| Income Tax | 0.6 | 0.5 | 0.1 | 0.2 | 0.1 | 1.0 | 0.8 | 0.0 |
| Net Income | -26.3 | -46.0 | -40.0 | -103.4 | -24.0 | -133.7 | -110.4 | -93.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on BMRA: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.